Wall Street analysts forecast that Applied Genetic Technologies Corporation (NASDAQ:AGTC) will announce earnings of ($0.18) per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Applied Genetic Technologies Corporation’s earnings, with the lowest EPS estimate coming in at ($0.28) and the highest estimate coming in at ($0.10). Applied Genetic Technologies Corporation reported earnings of $0.20 per share in the same quarter last year, which would suggest a negative year over year growth rate of 190%. The business is expected to issue its next earnings results on Tuesday, November 14th.

According to Zacks, analysts expect that Applied Genetic Technologies Corporation will report full-year earnings of ($0.75) per share for the current year, with EPS estimates ranging from ($1.23) to ($0.35). For the next financial year, analysts anticipate that the firm will post earnings of ($1.73) per share, with EPS estimates ranging from ($2.22) to ($0.69). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Applied Genetic Technologies Corporation.

Applied Genetic Technologies Corporation (NASDAQ:AGTC) last announced its quarterly earnings data on Wednesday, September 13th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.40). The firm had revenue of $8.30 million during the quarter, compared to the consensus estimate of $12.39 million. Applied Genetic Technologies Corporation had a net margin of 4.28% and a return on equity of 1.45%. The business’s revenue was down 31.4% compared to the same quarter last year. During the same period last year, the business earned $0.15 earnings per share.

A number of research firms recently weighed in on AGTC. HC Wainwright set a $16.00 target price on shares of Applied Genetic Technologies Corporation and gave the stock a “buy” rating in a report on Thursday, August 10th. Cantor Fitzgerald decreased their target price on shares of Applied Genetic Technologies Corporation from $15.00 to $9.00 and set a “neutral” rating on the stock in a report on Thursday, September 14th. Stifel Nicolaus decreased their target price on shares of Applied Genetic Technologies Corporation from $15.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, September 14th. Zacks Investment Research raised shares of Applied Genetic Technologies Corporation from a “sell” rating to a “hold” rating in a report on Tuesday, July 25th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $7.00 target price (down previously from $14.00) on shares of Applied Genetic Technologies Corporation in a report on Thursday, September 14th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $11.71.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/05/0-18-eps-expected-for-applied-genetic-technologies-corporation-agtc-this-quarter.html.

Shares of Applied Genetic Technologies Corporation (AGTC) traded up 2.44% on Thursday, reaching $4.20. 91,861 shares of the company were exchanged. The stock has a market capitalization of $75.97 million, a PE ratio of 210.00 and a beta of 1.63. The firm has a 50 day moving average price of $4.28 and a 200-day moving average price of $5.20. Applied Genetic Technologies Corporation has a 12-month low of $3.50 and a 12-month high of $10.85.

Several large investors have recently modified their holdings of AGTC. Teachers Advisors LLC increased its holdings in shares of Applied Genetic Technologies Corporation by 13.1% in the 4th quarter. Teachers Advisors LLC now owns 22,692 shares of the biotechnology company’s stock worth $212,000 after buying an additional 2,632 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Applied Genetic Technologies Corporation by 2.5% in the 1st quarter. Russell Investments Group Ltd. now owns 77,710 shares of the biotechnology company’s stock worth $535,000 after buying an additional 1,883 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of Applied Genetic Technologies Corporation by 1.1% in the 1st quarter. Wells Fargo & Company MN now owns 19,005 shares of the biotechnology company’s stock worth $131,000 after buying an additional 200 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Applied Genetic Technologies Corporation by 5.2% in the 1st quarter. Bank of New York Mellon Corp now owns 57,924 shares of the biotechnology company’s stock worth $400,000 after buying an additional 2,848 shares during the last quarter. Finally, Prudential Financial Inc. increased its holdings in shares of Applied Genetic Technologies Corporation by 24.2% in the 1st quarter. Prudential Financial Inc. now owns 155,210 shares of the biotechnology company’s stock worth $1,071,000 after buying an additional 30,200 shares during the last quarter. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

About Applied Genetic Technologies Corporation

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Get a free copy of the Zacks research report on Applied Genetic Technologies Corporation (AGTC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Applied Genetic Technologies Corporation (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.